查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138358

全球軍團菌檢測市場-2022-2029

Global Legionella Testing Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

主要驅動因素是肺炎和軍團菌相關疾病的發病率不斷上升，對快速和先進診斷技術的需求不斷增加，以及細菌學檢測技術的進步。

意識的提高和研發支出的增加正在推動全球市場的增長。

醫療保健意識的提高和投資的增加正在推動全球市場的增長。例如，西區公共衛生培訓中心參與開展退伍軍人疾病預防培訓。由 CDC 國家環境健康、免疫和呼吸系統疾病中心、國家公共衛生實驗室網絡、亞利桑那大學公共衛生學院 Mel 和 Enid Zuckerman 以及亞利桑那大學西部區域培訓中心開發的軍團菌水管理計劃培訓的此外，增加對醫療保健的投資也在振興全球市場。例如，根據歐洲製藥商協會聯合會的數據，2000 年製藥業的生產為歐洲經濟貢獻了 1275.04 億歐元，2010 年為 1997.3 億歐元，2019 年為 2932.13 億歐元，2020 年達到 310 億歐元.此外，研發支出在 2000 年為 178.49 億歐元，2010 年為 279.2 億歐元，2019 年為 377.54 億歐元，2020 年為 3900 億歐元。

與檢測相關的高昂成本和嚴格的政府立法限制了軍團菌檢測領域的發展。

發展中國家和欠發達國家的可支配收入短缺、診斷測試敏感性問題、與測試相關的高成本以及嚴格的政府法律。與測試相關的高成本可能會阻礙市場增長。例如，典型的費用從小型牙科診所和從業者的 200 英鎊到中型療養院的 500 英鎊不等。嚴格的政府法律的存在也阻礙了市場。例如，COSHH（對健康有害物質的控制條例）提供了一個行動框架來管理各種有害物質的風險，包括生物製品（如軍團菌）。它是識別和評估風險並實施必要的措施來控制所有風險。自 L8 批准的實踐守則（第 3 版）（ACOP）發布以來，商業機構和家庭機構的業主都必須評估其居住者暴露於軍團菌的風險。

行業分析

《全球軍團菌檢測報告》根據各種行業因素（包括波特五力、創新、新產品發布、定價等）對市場進行了深入分析。

COVID-19 影響分析

此後為防止 COVID-19 進一步傳播而實施的各種限制和法規已經影響了全球市場，使得開展影響市場的軍團菌檢測變得困難。此外，大流行還影響了許多發達和新興經濟體，使軍團菌檢測市場在爆發期間難以增長。

全球軍團菌檢測報告將提供大約 40 多個市場數據表、45 多個數字和大約 200 頁的訪問權限。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 提高認識
      • 研發費用增加
    • 限制因素
      • 與檢查相關的高成本
      • 嚴格的政府政策
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按測試類型

  • 尿抗原檢測 (UAT)
  • 培養方式
  • 直接熒光免疫分析 (DFA)
  • 聚合□鍊式反應 (PCR) 方法
  • 其他

第 8 章. 按應用程序

  • 臨床檢查方法
  • 環境檢查法

第 9 章抗生素

  • 阿奇黴素
  • 利福平
  • 奎諾酮類
  • 其他

第 10 章，最終用戶

  • 醫院
  • 診斷中心
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 13 章公司簡介

  • 雅培
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Albagaia Ltd
  • Aquacert Ltd
  • Becton, Dickinson and Company
  • BioMerieux SA
  • Idexx Laboratories Inc.
  • Merck Millipore
  • Pacific Water Technology
  • Phigenics LLC
  • Qiagen NV
  • Thermo Fisher Scientific Inc.

第14章 DataM

簡介目錄
Product Code: DMCD2149

Market Overview

Legionella Testing Market is expected to grow at a CAGR of 9.7% during the forecasting period (2022-2029).

Legionella is a bacterium that causes a severe form of pneumonia called Legionnaires disease or flu-like illness. Legionella testing aids in detecting the presence of bacteria to help diagnose the cause of a person's pneumonia.

Market Dynamics

The major driving forces are the rising incidence of pneumonia and legionella-related illnesses, increasing demand for rapid and advanced diagnostic techniques, and technological advancements in bacterial testing.

The increasing awareness and growing spending on research and development are driving the global market growth.

The growing awareness and increased investment in healthcare are fueling global market growth. For instance, Western Region Public Health Training Center is involved in providing training for Preventing Legionnaires' Disease: A Training over Legionella Water Management Programs, which is developed by the CDC's National Center for Environmental Health, Immunization and Respiratory Diseases, National Network of Public Health Institutes, College of the Public Health University of Arizona Mel and Enid Zuckerman and The Western Region Training Center at the University of Arizona. Furthermore, the increasing investment in healthcare is also fueling the global market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, in 2000, the production from the pharmaceutical industries contributed €127,504 million to Europe's economy, which reached €199,730 million in 2010, €293,213 million in 2019 and €310,000 million in 2020. Furthermore, the R&D expenditure was €17,849 million in 2000, €27,920 million in 2010, €37,754 million in 2019 and €39,000 million in 2020.

The high costs associated with the tests and strict government laws will restrain the global Legionella Testing growth.

The insufficient disposable income in developing and underdeveloped countries, issues in sensitivity of diagnostic tests, high costs associated with the tests, and strict government laws. The high costs associated with the tests will likely hamper the market growth. For instance, typical costs range from £200.00 for a small dental or GP practice to £500.00 for a medium-sized care home. The presence of strict government laws is also hindering the market. For instance, The Control of Substances Hazardous to Health Regulations (COSHH) gives a framework of actions to control the risk from a range of hazardous substances, including biological agents (e.g., Legionella) - to identify and evaluate the risk and implement any necessary measures to control any risk. Since the L8 Approved Code of Practice (3rd edition) (ACOP) was published, there has been a requirement for landlords of both business premises and domestic premises to evaluate the risks from exposure to Legionella to their tenants.

Industry analysis.

The global legionella testing report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing Etc.

COVID-19 Impact Analysis

Different restrictions and regulations forced to prevent further COVID-19 infection spread have impacted the global market since, making it difficult for people to perform legionella testing affecting the market. Furthermore, the pandemic has also affected many developed and developing countries economies, making it difficult for the legionella testing market to grow during the outburst.

Segment Analysis

Urinary antigen testing is expected to have a large share of the Legionella Testing market during the forecast period (2022-2029).

The Urinary Antigen Test segment is expected to grow rapidly over the forecast period (2022-2029). UAT is a diagnostic tool that offers same-day results. Further, UAT is not resource-specific and technically intensive like the culture tests. Since the urinary antigen test does not require respiratory fluid samples, sensitivity issues are also reduced. Thus, UAT remains the test of choice for clinicians and diagnostic experts primarily because of its ease of handling, rapid testing advantage, increased sensitivity, and specificity. For instance, according to the CDC, it has 70-100% sensitivity and 95-100% specificity. Also, the presence of research and development activities on urinary antigen tests is driving the market. Furthermore, a research study on the novel Legionella urinary antigen test kit for diagnosing Legionella pneumonia showed that it could detect Legionella pneumonia caused by non-L. pneumophila serogroup.

Geographical Analysis

North America is dominating the global legionella testing market.

North America dominated the global legionella testing market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the rising incidence of legionellosis and the presence of key players in the region. For instance, according to the Occupational Safety and Health Administration, around 6,000 Legionnaires' disease cases are reported annually in the United States. U.S. population-based study estimated that 8,000-18,000 people are hospitalized yearly with Legionnaires' disease. Furthermore, most market key players have a large portion of the global market, such as Becton, Dickinson and Company, Idexx Laboratories Inc., Phigenics LLC, Thermo Fisher Scientific Inc. and Abbott, ensure that North America commands the global legionella testing market. Moreover, North America has the most advanced and robust healthcare infrastructure and better healthcare cost reimbursement policies.

Competitive Landscape

The major players operating in the global legionella testing market are Albagaia Ltd, Aquacert Ltd, Becton, Dickinson and Company, BioMerieux SA, Idexx Laboratories Inc., Merck Millipore, Pacific Water Technology, Phigenics LLC, Abbott, Qiagen NV, and Thermo Fisher Scientific Inc. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the legionella testing market globally. For instance, on February 23, 2022, Thermo Fisher Scientific Inc. and Moderna entered a long-term collaboration.

Abbott

Overview:

Abbott Laboratories is a leading American healthcare and medical devices innovator and producer headquartered in Illinois, United States, established in 1888. Abbott Laboratories is currently involved in dealing with medical devices, diagnostics, branded generic medicines and nutritional products.

Product Portfolio:

The product portfolio of Abbott for Legionella Testing has BINAX™ LEGIONELLA URINARY ANTIGEN EIA, Etc.

The global legionella testing report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Awareness
      • 4.1.1.2. Growing Research and Development Spending
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost Associated with Tests
      • 4.1.2.2. Strict Government Policies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Urinary Antigen Test (UAT)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Culture Methods
  • 7.4. Direct Fluorescent Antibody Test (DFA)
  • 7.5. Polymerase Chain Reaction (PCR)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Clinical Testing Methods
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Environmental Testing Methods

9. By Antibiotics

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotics Segment
    • 9.1.2. Market Attractiveness Index, By Antibiotics Segment
  • 9.2. Azithromycin
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Rifampin
  • 9.4. Quinolones
  • 9.5. Others

10. By End-user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 10.1.2. Market Attractiveness Index, By End-user Segment
  • 10.2. Hospitals
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Antibiotic
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Abbott
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Albagaia Ltd
  • 13.3. Aquacert Ltd
  • 13.4. Becton, Dickinson and Company
  • 13.5. BioMerieux SA
  • 13.6. Idexx Laboratories Inc.
  • 13.7. Merck Millipore
  • 13.8. Pacific Water Technology
  • 13.9. Phigenics LLC
  • 13.10. Qiagen NV
  • 13.11. Thermo Fisher Scientific Inc.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us